Loading stock data…
$2.33-0.16 (-6.60%)
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States.
PepGen Inc. in the Healthcare sector is trading at $2.50 with a market capitalization of $197M. Wall Street consensus targets $10.19 (8 analysts), implying a +307.5% move over the next 12 months. The stock is currently near its 52-week low of $1.31, remaining 23.8% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$18.94M | -$18.94M↑ | -$19.70M↓ | -$18.65M↑ | -$23.93M |
| Net Income | -$17.81M↓ | -$17.76M↑ | -$18.34M↓ | -$18.03M↑ | -$23.09M |
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-co...